{
    "clinical_study": {
        "@rank": "124306", 
        "arm_group": [
            {
                "arm_group_label": "Patients admitted to the Intensive Care Unit", 
                "description": "All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study."
            }, 
            {
                "arm_group_label": "Patients admitted to the hematology ward", 
                "description": "All patients admitted to the Hematology ward, treated with voriconazole are eligible for the study."
            }, 
            {
                "arm_group_label": "Patients admitted to the pediatric ward", 
                "description": "All patients admitted to the Pediatric ward, treated with voriconazole are eligible for the study."
            }
        ], 
        "biospec_descr": {
            "textblock": "Plasma and serum samples are obtained to determine the albumin and alpha-1-acid-glycoprotein\n      level."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the protein binding characteristics of the\n      antifungal drug voriconazole in different patient populations, both to albumin and\n      alpha-1-acid-glycoprotein."
        }, 
        "brief_title": "Plasma Protein Binding Characteristics of Voriconazole", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Focus of the Study:Protein Binding Characteristics of Voriconazole.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  treated with voriconazole\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients admitted to the intensive care unit, hematology ward, pediatric ward, treated\n        with voriconazole."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812473", 
            "org_study_id": "ML8949", 
            "secondary_id": "2013-000559-42"
        }, 
        "intervention": {
            "arm_group_label": [
                "Patients admitted to the Intensive Care Unit", 
                "Patients admitted to the hematology ward", 
                "Patients admitted to the pediatric ward"
            ], 
            "description": "During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.", 
            "intervention_name": "Blood sampling", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Voriconazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "protein binding", 
            "voriconazole", 
            "pediatrics", 
            "hematology", 
            "intensive care", 
            "albumin", 
            "alpha-1-acid-glycoprotein"
        ], 
        "lastchanged_date": "March 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "state": "Vlaams-Brabant", 
                    "zip": "3000"
                }, 
                "name": "University Hospitals Leuven"
            }, 
            "investigator": [
                {
                    "last_name": "Kim Vanstraelen, PharmD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Isabel Spriet, PharmD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joost Wauters, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Johan Maertens, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katrien Lagrou, PharmD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "3", 
        "official_title": "Plasma Protein Binding Characteristics of Voriconazole in Specific Subsets of Patients", 
        "overall_contact": {
            "email": "kim.vanstraelen@uzleuven.be", 
            "last_name": "Kim Vanstraelen, PharmD", 
            "phone": "(+32) (0) 16 342339"
        }, 
        "overall_official": {
            "affiliation": "Universitaire Ziekenhuizen Leuven", 
            "last_name": "Kim Vanstraelen, PharmD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "At steady state plasma concentrations of voriconazole, a plasma sample is taken to determine the overall protein binding of voriconazole. Equilibrium dialysis is used, followed by liquid chromatography-mass spectrometry.", 
            "measure": "Differences in overall protein binding between different patient groups", 
            "safety_issue": "No", 
            "time_frame": "At steady state plasma concentration of voriconazole (after day 4 of therapy)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "At steady state plasma concentrations of voriconazole, at the same time of plasma sampling for overall protein binding determination, albumin level is determined. A serum sample is also taken to determine the alpha-1-acid-glycoprotein. In this way, variations in overall protein binding can be correlated with variations in both plasma proteins.", 
            "measure": "Protein binding characteristics of voriconazole to albumin and alpha-1-acid-glycoprotein", 
            "safety_issue": "No", 
            "time_frame": "At steady state plasma concentration of voriconazole (after day 4 of therapy)"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}